cyc 202 has been researched along with oxalates in 2 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (oxalates) | Trials (oxalates) | Recent Studies (post-2010) (oxalates) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 6,946 | 136 | 1,162 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dvorák, Z; Popa, I; Starha, P; Trávnícek, Z; Vrzal, R | 1 |
| Chalupová, M; Hošek, J; Štarha, P; Suchý, P; Trávníček, Z; Vančo, J | 1 |
2 other study(ies) available for cyc 202 and oxalates
| Article | Year |
|---|---|
Roscovitine-based CDK inhibitors acting as N-donor ligands in the platinum(II) oxalato complexes: preparation, characterization and in vitro cytotoxicity.
Topics: Antineoplastic Agents; Cell Line; Cell Survival; Cells, Cultured; Cyclin-Dependent Kinases; Hepatocytes; Humans; Neoplasms; Organoplatinum Compounds; Oxalates; Protein Kinase Inhibitors; Purines; Roscovitine; Spectrum Analysis | 2010 |
Platinum(II)-oxalato complexes of seliciclib (CYC202) derivatives show different cellular effects and lesser adverse effects in mouse lymphoma model than cisplatin.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Humans; Lymphoma; Male; Mice; Mice, Inbred DBA; Organoplatinum Compounds; Oxalates; Roscovitine | 2020 |